Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain-Reference-Cited by-同舟云学术

Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain

Published:2023-02-21 Issue:3 Volume:7 Page:431-441
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Alonso Torres A. M.^ORCID,Arévalo Bernabé A. G.,Becerril Ríos N.^ORCID,Hellín Gil M. F.^ORCID,Martínez Sesmero J. M.^ORCID,Meca Lallana V.^ORCID,Ramió-Torrentà Ll.^ORCID,Rodríguez-Antigüedad A.^ORCID,Gómez Maldonado L.^ORCID,Triana Junco I.,Gómez-Barrera M.^ORCID,Espinoza Cámac N.^ORCID,Oyagüez I.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s41669-023-00394-2.pdf

Reference40 articles.

1. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378:169–80. https://doi.org/10.1056/NEJMra1401483.

2. García Merino A, Ramón Ara Callizo J, Fernández Fernández O, Landete Pascual L, Moral Torres E, Rodríguez-Antigüedad Zarrantz A. Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016. Neurol Barc Spain. 2017;32:113–9. https://doi.org/10.1016/j.nrl.2016.02.026.

3. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–86. https://doi.org/10.1212/WNL.0000000000000560.

4. Arrambide G, Iacobaeus E, Amato MP, Derfuss T, Vukusic S, Hemmer B, et al. Aggressive multiple sclerosis (2): treatment. Mult Scler J. 2020;26:1045–63. https://doi.org/10.1177/1352458520924595.

5. Perez-Carmona N, Fernandez-Jover E, Sempere AP. Epidemiology of multiple sclerosis in Spain. Rev Neurol. 2019;69:32–8. https://doi.org/10.33588/rn.6901.2018477.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative efficacy of subcutaneous versus intravenous natalizumab on annualized relapse rate: A post-hoc analysis of the REFINE study;Multiple Sclerosis and Related Disorders;2024-11

2. Budget impact analysis of natalizumab biosimilar on pharmaceutical expenditure for the treatment of relapsing-remitting multiple sclerosis in Italy;AboutOpen;2024-06-17

3. Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis;Neurological Sciences;2024-01-26

4. Drug Expenditure, Price, and Utilization in US Medicaid: A Trend Analysis for New Multiple Myeloma Medications from 2016 to 2022;Healthcare;2023-08-11

5. The first Polish experiences with SC natalizumab;Aktualności Neurologiczne;2023-05-29